[SCHEDULE 13D/A] Galecto, Inc. SEC Filing

Rhea-AI Filing Summary

Novo Holdings A/S reports holding 86,579 shares of Galecto, Inc. common stock, representing approximately 6.5% of the 1,324,560 shares outstanding as of August 1, 2025. The Schedule 13D/A updates prior filings and states that Novo Holdings has sole voting and dispositive power over the shares it holds.

The filing discloses that on September 23, 2025, Novo Holdings sold 13,334 shares in open market transactions at prices between $4.00 and $4.85, with a weighted average sales price of $4.2295 per share. The statement clarifies Novo Holdings role as a Danish holding company managing assets of the Novo Nordisk Foundation and confirms no convictions or disqualifying civil judgments in the past five years for the reporting entities or listed officers.

Positive

• Clear disclosure of beneficial ownership: 86,579 shares representing 6.5% of outstanding common stock
• Sole voting and dispositive power over the reported shares, confirming voting clarity
• Transparent transaction detail for the September 23, 2025 sale, including price range and weighted average

Negative

• Open-market sale disclosed: 13,334 shares sold on September 23, 2025, which reduces holdings via public transactions
• Stake below control threshold: 6.5% ownership is material but does not confer control

Insights

Financial Analyst

TL;DR: Novo Holdings holds a meaningful 6.5% stake in Galecto and disclosed a recent small open-market sale.

Novo Holdings 6.5% position is large enough to be material for investors monitoring ownership concentration but does not constitute control. The filing confirms sole voting and dispositive authority, which means Novo can independently vote its shares. The disclosed sale of 13,334 shares on September 23, 2025, is quantified with prices and a weighted average of $4.2295, providing clear transactional transparency. Overall, this Schedule 13D/A is routine disclosure of an existing strategic investors stake and a small sale; it does not include any new agreements, board nominations, or change-of-control proposals.

Corporate Governance Expert

TL;DR: Filing documents beneficial ownership and voting power clearly; no governance actions or arrangements are reported.

The amendment reiterates that Novo Holdings A/S has sole voting and dispositive power over its 86,579 shares and that the Novo Nordisk Foundation is not deemed the beneficial owner. The Schedule I update and repeated amendments demonstrate compliance and transparency. There are no disclosures of derivative positions, agreements to act with others, or planned governance changes, so the filing indicates passive ownership rather than an active governance campaign.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

Galecto, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

36322Q107

(CUSIP Number)

Barbara Fiorini
Novo Holdings A/S, Tuborg Havnevej 19
Hellerup, G7, DK-2900
45 3527 6592

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/23/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 36322Q107

1

Name of reporting person

Novo Holdings A/S

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DENMARK

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 86,579.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 86,579.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

86,579.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.5 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.00001 per share
(b)	Name of Issuer: Galecto, Inc.
(c)	Address of Issuer's Principal Executive Offices: 75 State Street, Suite 100, Boston, MASSACHUSETTS , 02109.
Item 1 Comment: This Amendment No. 4 (this "Amendment No. 4" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on November 5, 2020, and amended on September 30, 2022, June 24, 2024 and January 16, 2025 (as amended, the "Statement") by Novo Holdings A/S. Unless otherwise defined herein, capitalized terms used in this Amendment No. 4 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
Item 2.	Identity and Background
(a)	Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the "Foundation"), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies, currently comprised of Novo Nordisk A/S and Novozymes A/S (trade name: Novonesis A/S), and is responsible for managing the Foundation's assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S. The name of each director and executive officer of both Novo Holdings A/S and the Foundation is set forth on the updated Schedule I to this Amendment No. 4.
(b)	The business address of both Novo Holdings A/S and the Foundation is Tuborg Havnevej 19, 2900 Hellerup, Denmark. The residence or business address of each director and executive officer of both Novo Holdings A/S and the Foundation is set forth on the updated Schedule I to this Amendment No. 4.
(c)	Novo Holdings A/S, a holding company that is responsible for managing the Foundation's assets, provides seed and venture capital to development stage companies and invests in well established companies within the life science and biotechnology sector. The Foundation is a Danish self-governing and profit-making foundation, whose objectives are to provide a stable basis for commercial and research activities undertaken by the group of Novo companies and to support scientific, humanitarian and social purposes through grants.
(d)	Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in the updated Schedule I has been convicted in any criminal proceedings.
(e)	Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in the updated Schedule I was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Denmark
Item 5.	Interest in Securities of the Issuer
(a)	Novo Holdings A/S beneficially owns 86,579 shares of Common Stock representing approximately 6.5% of the Issuer's outstanding shares of Common Stock, based upon 1,324,560 shares of the Common Stock outstanding as of August 1, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 5, 2025.
(b)	Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on the updated Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.
(c)	Except as described below, Novo Holdings A/S has not effected any transactions in the Issuer's Common Shares within the past 60 days and neither the Foundation nor any person listed on the updated Schedule I has effected any transactions in the Issuer's Common Shares within the past 60 days. On September 23, 2025, Novo Holdings A/S sold an aggregate of 13,334 shares of Common Stock in open market transactions at prices ranging from $4.00 to $4.85 (weighted average sales price of $4.2295 per share).
(d)	Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares.
(e)	Not applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 Schedule I

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Novo Holdings A/S

Signature:	/s/ Barbara Fiorini
Name/Title:	By Barbara Fiorini, General Counsel, Finance & Operations
Date:	09/25/2025

FAQ

How many Galecto (GLTO) shares does Novo Holdings A/S report owning?

Novo Holdings A/S reports beneficially owning 86,579 shares of Galecto common stock.

What percentage of GLTO does Novo Holdings A/S own?

The filing states this represents approximately 6.5% of Galecto's outstanding common stock based on 1,324,560 shares outstanding as of August 1, 2025.

Did Novo Holdings A/S trade any GLTO shares recently?

Yes. On September 23, 2025, Novo Holdings A/S sold 13,334 shares in open-market transactions at prices between $4.00 and $4.85 with a weighted average of $4.2295.

Does Novo Holdings A/S have voting control over its GLTO shares?

Yes. The filing states Novo Holdings A/S has sole voting and dispositive power over the reported shares.

Is the Novo Nordisk Foundation deemed the beneficial owner of the reported GLTO shares?

No. The filing explains that the Foundation is not deemed to have beneficial ownership of the securities held by Novo Holdings A/S.